[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339968-105":59,"doc-detail-339968-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","methylated-dna-markers-in-voided-urine-for-the-identification-of-clinically-significant-prostate-cancer","Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer","","Non-invasive assays are needed to better distinguish men with prostate cancer and reduce overtreatment of indolent disease. The study analyzed 14 methylated DNA markers from urine samples of biopsy-proven prostate cancer patients versus healthy controls, and evaluated discrimination for clinically significant prostate cancer. Using a 100% specificity cut-off, the marker panel achieved 71% sensitivity for prostate cancer detection and 76% sensitivity for clinically significant prostate cancer (Gleason ≥ 7).",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/methylated-dna-markers-in-voided-urine-for-the-identification-of-clinically-significant-prostate-cancer/339968/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/methylated-dna-markers-in-voided-urine-for-the-identification-of-clinically-significant-prostate-cancer/339968.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in prostate cancer screening?","Question",{"text":112,"@type":113},"Non-invasive assays are needed to discriminate patients with clinically significant prostate cancer and avoid over-treatment of indolent disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the methylated DNA markers measured in this research?",{"text":117,"@type":113},"DNA from urine supernatant was analyzed for methylation signals across specific DNA sequences spanning 14 genes using target enrichment long-probe quantitative-amplified signal assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What performance did the methylated DNA marker panel show at 100% specificity?",{"text":121,"@type":113},"With a 100% specificity cut-off for controls versus prostate cancer cases, sensitivity was 71% for prostate cancer detection and 76% for clinically significant prostate cancer (Gleason ≥ 7).",{"name":123,"@type":110,"acceptedAnswer":124},"Is prospective validation planned?",{"text":125,"@type":113},"Yes. Prospective evaluation is needed to estimate discrimination of patients as first-line screening and as an adjunct to PSA testing.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},339968,1790160329,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","life  \nBrief Report  \nMethylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer  \nParas Shah 1, William R. Taylor 2, Brianna J. Negaard 2, Benjamin R. Gochanour 3, Douglas W. Mahoney 3, Sara S. Then 2, Mary E. Devens 2, Patrick H. Foote 2, Karen A. Doering 2, Kelli N. Burger 3, Brandon Nikolai 4, Michael W. Kaiser 4, Hatim T. Allawi 4, John C. Cheville 5, John B. Kisiel 2 and Matthew T. Gettman 1, *  \nCitation: Shah, P.; Taylor, W.R.; Negaard, B.J.; Gochanour, B.R.; Mahoney, D.W.; Then, S.S.; Devens, M.E.; Foote, P.H.; Doering, K.A.; Burger, K.N.; et al. Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer. Life 2024, 14, 1024 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)life14081024  \nAcademic Editor: Vittoria Rago  \nReceived: 13 June 2024  \nRevised: 12 August 2024  \nAccepted: 14 August 2024  \nPublished: 18 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Urology, Mayo Clinic, Rochester, MN 55905, USA; [shah.paras@mayo.edu](shah.paras@mayo.edu)  \n2 Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA; [wtaylor@mayo.edu](wtaylor@mayo.edu) (W.R.T.); [gysbers.brianna@mayo.edu](gysbers.brianna@mayo.edu) (B.J.N.); [then.sara@mayo.edu](then.sara@mayo.edu) (S.S.T.); [devens@mayo.edu](devens@mayo.edu) (M.E.D.);  \n[foote.patrick@mayo.edu](foote.patrick@mayo.edu) (P.H.F.); [doering.karen@mayo.edu](doering.karen@mayo.edu) (K.A.D.); [kisiel.john@mayo.edu](kisiel.john@mayo.edu) (J.B.K.)  \n3 Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA; [gochanour.benjamin@mayo.edu](gochanour.benjamin@mayo.edu) (B.R.G.); [mahoney@mayo.edu](mahoney@mayo.edu) (D.W.M.); [burger.kelli@mayo.edu](burger.kelli@mayo.edu) (K.N.B.)  \n4 Exact Sciences Corporation, Madison, WI 53719, USA; [bnikolai@exactsciences.com](bnikolai@exactsciences.com) (B.N.); [mkaiser@exactsciences.com](mkaiser@exactsciences.com) (M.W.K.); [hallawi@exactsciences.com](hallawi@exactsciences.com) (H.T.A.)  \n5 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA; [cheville.john@mayo.edu](cheville.john@mayo.edu)  \n* Correspondence: [gettman.matthew@mayo.edu](gettman.matthew@mayo.edu)  \nAbstract: Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76%(50–92%) for csPCa (Gleason ≥ 7) . At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59%(33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+) . Conclusions: MDMs assayed ","cbCaieBH2rdmwwX0","https://ap.wps.com/l/cbCaieBH2rdmwwX0","pdf",2354741,13,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What problem does the study address in prostate cancer screening?\",\"answer\":\"Non-invasive assays are needed to discriminate patients with clinically significant prostate cancer and avoid over-treatment of indolent disease.\"},{\"question\":\"How were the methylated DNA markers measured in this research?\",\"answer\":\"DNA from urine supernatant was analyzed for methylation signals across specific DNA sequences spanning 14 genes using target enrichment long-probe quantitative-amplified signal assays.\"},{\"question\":\"What performance did the methylated DNA marker panel show at 100% specificity?\",\"answer\":\"With a 100% specificity cut-off for controls versus prostate cancer cases, sensitivity was 71% for prostate cancer detection and 76% for clinically significant prostate cancer (Gleason ≥ 7).\"},{\"question\":\"Is prospective validation planned?\",\"answer\":\"Yes. Prospective evaluation is needed to estimate discrimination of patients as first-line screening and as an adjunct to PSA testing.\"}]","Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer | PDF",1790033403,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5a12c957c33539c3a00ddae842b835f.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20ce7e8ce1129e6659b143c3612cfe61.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9518a7ea1ad0d363d6955cb47d29fef7.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fb8014d8ebe4f486f21a17b6489be5d.webp",980,1385]